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Abstract
Background: Metabolic syndrome (MS) occurs frequently in patients with obstructive sleep apnea-hypopnea syndrome
(OSAHS). We hypothesized that aldosterone levels are elevated in OSAHS and associated with the presence of MS.
Methods: We studied 66 patients with OSAHS (33 with MS and 33 without MS) and 35 controls. The occurrence of the MS
was analyzed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) clinical
criteria. Measurements of plasma renin activity (PRA), aldosterone, aldosterone:PRA ratio, creatinine, glucose, triglycerides,
cholesterol and HDL cholesterol were obtained at baseline and after CPAP treatment.
Results: Aldosterone levels were associated with the severity of OSAHS and higher than controls (p = 0.046). Significant
differences in aldosterone levels were detected between OSAHS patients with and without MS (p = 0.041). A significant
reduction was observed in the aldosterone levels in patients under CPAP treatment (p = 0.012).
Conclusion: This study shows that aldosterone levels are elevated in OSAHS in comparison to controls, and that CPAP
therapy reduces aldosterone levels. It also shows that aldosterone levels are associated with the presence of metabolic
syndrome, suggesting that aldosterone excess might predispose or aggravate the metabolic and cardiovascular
complications of OSAHS.
Trial registration: The study is not a randomized controlled trial and was not registered.
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Introduction
Current data indicate that obstructive sleep apnea-hypopnea
syndrome (OSAHS) is highly associated with the metabolic
syndrome (MS) [1]–[3] The underlying mechanistic links between
OSAHS and the metabolic syndrome have not been well
delineated.
There is a close relationship between the Renin-Angiotensin-
Aldosterone (RAS) system and hypertension [4]–[6]. Furthermore,
recent evidence involves aldosterone in the pathogenesis of
metabolic syndrome [7],[8]. Findings from observational studies
demonstrated that high aldosterone levels are associated with
impaired pancreatic b-cell function and insulin resistance and
long-term clinical trials of antihypertensive agents have shown that
direct inhibitors of the RAS system (angiotensin converting
enzyme inhibitors and angiotensin receptor blockers) significantly
improved insulin sensitivity and reduced the risk of incident
diabetes[9]. Several cross-sectional studies have demonstrated that
higher aldosterone levels are associated with a greater prevalence
of MS and components of MS[10–13]. In the Framingham
Offspring study aldosterone was found to correlate positively with
both the development of the MS and an increase in systolic blood
pressure, indicating that aldosterone would predict the onset of
hypertension and the MS[14].
It has been suggested that activation of the RAS system, in
particular aldosterone excess, may play a pathophysiological role
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in the relation between OSAHS and hypertension[15],[16]. The
possibility that this activation may contribute to the development
of the metabolic syndrome in OSAHS is unknown. We
hypothesized that hyperaldosteronism is highly prevalent in
OSAHS and also associated with the presence of MS. To test
this hypothesis, we evaluated the plasma aldosterone concentra-
tions (PAC) and plasma aldosterone: renin activity (PRA) ratio in
patients with OSAHS (with and without MS) and controls without
MS. Patients were re-examined after 12 months of effective
treatment with continuous positive airway pressure (CPAP).
Methods
Subjects and ethics
We included in the study 66 male patients with OSAHS (33
with MS and 33 without MS). Patients were matched for age (65
years) and BMI (63 Kg.m22). As a reference group, we studied 35
controls without MS. Participants were recruited from subjects
who attended our sleep unit. No participant suffered from any
other chronic disease (diabetes, chronic obstructive pulmonary
disease (COPD), liver cirrhosis, thyroid dysfunction, rheumatoid
arthritis, chronic renal failure and/or psychiatric disorders). In
addition, the enrolled participants were taking no antihypertensive
medications and there were no differences between the number of
patients and controls taking hypoglycemic, hypolipemiant and/or
anti-inflammatory agents.
Each patient was studied at diagnosis and after effective
treatment with CPAP (REM Star, Respironics H, Murrysville,
PA, USA) during 12 months. Fifteen patients who did not use the
device for a minimum of 4 h/night or did not return for the
follow-up visit at 12 months were excluded from the follow-up
analysis. The study was approved by the Ethics Committee of our
institution, ‘‘Comite` E`tic d’Investigacio´ Clı´nica Illes Balears’’, and
all participants signed their consent after being fully informed of its
goal and characteristics.
Measurements and definitions
The diagnosis of OSAHS was established by full polysomno-
graphy (E-Series Compumedics, Abbotsford, Australia), which
included recording of oronasal flow, thoracoabdominal move-
ments, electrocardiography, submental and pretibial electromyog-
raphy, electrooculography, electroencefalography and trancuta-
neous measurement of arterial oxygen saturation. Apnea was
defined by the absence of airflow for more than 10 seconds.
Hypopnea was defined as any airflow reduction that last more
than 10 seconds and resulted in arousal or oxygen desaturation.
We considered desaturation a decrease in SaO2 greater than 4%.
The apnea-hypopnea index (AHI) was defined as the sum of the
number of apneas plus hypopneas per hour of sleep. The case or
control status was defined by the AHI threshold of 10 or greater.
Excessive daytime sleepiness (EDS) was subjectively quantified by
the Epworth sleepiness scale (ESS).
The occurrence of the MS was analyzed according to the
National Cholesterol Education Program Adult Treatment Panel
III (NCEP ATP III) clinical criteria: (1) waist circumference $
94 cm in men and $88 cm in women, (2) fasting glucose $
100 mg/dL or patient on specific drug treatment, (3) triglycerides
$150 mg/dL or patient on specific treatment, (4) HDL cholesterol
(HDLc) ,40 mg/dL in men and ,50 mg/dL in women or
patient on specific drug treatment, (5) systolic blood pressure (SBP)
$130 mmHg or diastolic blood pressure(DBP) $85 mmHg or
patient on specific drug treatment. The MS was diagnosed if 3 of
these 5 factors were present.
After fasting overnight, venous blood samples were obtained
between 8 and 10 am. Blood was centrifuged and plasma and
serum were immediately separated in aliquots and stored at –80uC
until analysis.
Glucose, triglycerides, total cholesterol, HDL cholesterol
(HDLc), and creatinine were determined by standard enzymatic
methods on a Hitachi Modular analyzer (Roche Diagnostics,
Indianapolis, USA). Plasma renin activity (PRA) and serum
aldosterone were measured by radioimmunoassay methods (DPC
Biermann, Bad Nauheim, Germany). Hyperaldosteronism was
defined as an aldosterone:PRA ratio at least 30 (ng/dL/ng/mL/h)
and/or a plasma aldosterone more than 20 ng/dL.
Statistical analysis
Results are presented as percentages or mean 6 standard
deviations. Comparisons between groups were performed by
Kruskal Wallis or ANOVA test for continuous variables and x2
test for categorical variables.
The effects of CPAP therapy were analyzed using paired t-tests
(Wilcoxon or McNemar test).
Correlations between variables were explored using the
Spearman-rank test.
In order to evaluate the relationships between OSAHS,
aldosterone and the metabolic syndrome, logistic regression
models were calculated with MS and its components as dependent
and aldosterone as independent variables after adjusting for age
and BMI.
A p value lower than 0.05 was considered significant. The SPSS
v.18 software was used for all analyses.
Results
Characteristics of the study population are summarized in
Table 1. By design, age and BMI were similar in patients with and
without MS.
Aldosterone levels were significantly higher in OSAHS patients
than in subjects without OSAHS (p = 0.046). Furthermore,
What is the key question?
Are aldosterone levels elevated in patients with obstruc-
tive sleep apnea-hypopnea syndrome (OSAHS), and
associated with the presence of metabolic syndrome (MS)?
What is the bottom line?
Current data indicate that OSAHS is highly associated with
MS. The underlying mechanistic links between OSAHS and
MS are not well delineated to date.
There is a close relationship between the Renin-Angioten-
sin-Aldosterone system and hypertension, and recent
evidence involves aldosterone in the pathogenesis of MS.
Why read on?
These findings show that aldosterone levels are elevated in
OSAHS in comparison to controls, and continuous positive
airway pressure (CPAP) therapy reduces aldosterone levels.
They also show that aldosterone levels are associated with
the presence of metabolic syndrome, suggesting a
potential role of aldosterone excess in the development
of metabolic and cardiovascular complications in patients
with OSAHS.
Aldosterone and OSA
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significant differences in aldosterone levels were detected between
OSAHS patients with and without MS (p = 0.041).
In the OSAHS group, aldosterone levels were significantly
related to AHI (r = 0.225, p = 0.016) and to arousal index
(r = 0.269, p = 0.05), (Figure1, panels a and b, respectively).
Likewise, aldosterone levels were also significantly related to waist
circumference (r = 0.431, p = 0.006), triglyceride levels (r = 0.395,
p = 0.001) and HDL cholesterol levels (r = 0.439, p = 0.001),
(Figure 2, panels a, b, c)
Aldosterone levels tended to be higher in hypertensive patients
(19.2612.2 ng/dL, n = 14) than in normotensive patients
(15.368.6 ng/dL), although differences did not reach statistical
significance (p = 0.142).
In a multiple regression analysis, a meaningful association
between aldosterone levels and the presence of metabolic
Table 1. Subject characteristics.
OSAHS with MS (n=33) OSAHS without MS (n=33) Controls (n =35)
Age (years) 5268** 4969** 42615
BMI (Kg.m 22) 3263** 2964** 2664
AHI (hour 21) 53624** 45618** 562
Mean Sat O2(%) 9263** 9362** 9662
Minimal Sat O2(%) 7869** 8266** 9063
Epworth scale 1064 964 963
Arousal index 64622** 52616** 19612
Waist circumference (cm) 11068** 10469** 94611
Glucose (mg/dL) 117622* 98610 95618
Triglycerides (mg/dL) 236661* 127662 112646
HDLc (mg/dL) 4669 55612 52610
SBP (mmHg) 141615* 125615* 118613
DBP (mmHg) 88610* 79610* 7268
Creatinine (mg/dL) 0.9460.15 0.9660.11 0.9460.12
PRA (ng/mL/h) 1.361.2 1.961.1 1.361.1
Aldosterone (ng/dL) 17.869.4* 14.869.7* 13.167.4
Aldosterone/PRA ratio 21615 19617 17615
Hyperaldosteronism (n,%) (9, 28%)* (3,10%) (2, 6%)
**p,0.01, * p,0.05 versus controls,
"p,0.05 versus OSAHS without MS.
doi:10.1371/journal.pone.0084362.t001
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syndrome was found. In addition, aldosterone levels were
associated with the presence of elevated blood pressure ($130/
85 mmHg) and elevated triglyceride levels ($150 mg/dL),
according to criteria for the MS. Aldosterone levels tended to
increase with an increasing number of MS risk factors (p = 0.08),
(Figure 3).
Four patients with MS showed glucose levels higher than
126 mg/dL (threshold value for defining diabetes), although their
exclusion would not change initial results.
The results of the metabolic parameters at baseline and at the
follow-up examination are shown in table 2. A statistically
significant reduction was observed in the levels of aldosterone in
patients under CPAP treatment, without significant changes in
PRA and aldosterone/PRA ratio. They also manifested a
significant increase in HDLc cholesterol compared to baseline
despite similar BMI. There were no significant variations in waist
circumference, SBP, DBP, glucose or triglyceride levels.
Discussion
The results of this study show that aldosterone levels are
associated to the severity of OSAHS and that CPAP therapy
reduces aldosterone levels. They also show that aldosterone levels
are associated with the presence of metabolic syndrome, suggest-
ing that aldosterone excess might predispose or aggravate the
metabolic and cardiovascular complications of OSAHS.
The relation between OSAHS and the renin-angiotensin-
aldosterone system (RAS) is complex and data are not uniform.
Aldosterone is synthesized by the adrenal gland in response to
angiotensin II, potassium and adrenocorticotrophin hormone
(ACTH). In addition, obesity is associated with increased levels
of the circulating RAS components [24]–[28]. The adipose tissue
is an important source of the renin substrate (angiotensinogen), but
other mediators can stimulate aldosterone synthesis independently
of angiotensin II, as well [8],[29]. Experimental studies have
shown that adipocytes may release adipokines and free fatty acids
that could either directly or indirectly stimulate aldosterone
secretion by adrenocortical cells [30]–[32]. In our study,
aldosterone levels were higher in OSAHS patients than in
controls. We also found a significant correlation between
aldosterone levels (but not PRA) and AHI and arousal index,
suggesting that sleep fragmentation and repetitive arousals may
influence aldosterone secretion in patients with OSAHS. Aldoste-
rone could be elevated by a repeated stresses-based mechanism,
which could impact ACTH release and/or by additional RAS-
independent stimulus. This interpretation is further supported by
the observation that treatment of OSAHS with CPAP reduces
aldosterone levels, without modifying BMI and PRA levels.
Figure 2. Relationship between aldosterone and waist circumference (panel a), triglycerides (panel b), and HDL cholesterol (panel
c) in the OSAHS population studied.
doi:10.1371/journal.pone.0084362.g002
Aldosterone and OSA
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Recent studies involve aldosterone in the pathogenesis of the
metabolic syndrome [33],[34]. Elevated aldosterone levels have
been pointed to lead not only to sodium retention and volume
expansion, but also to increased inflammation and oxidative stress,
which in turn promote insulin resistance, impaired pancreatic b
cell function, endothelial dysfunction and hypertension [35],[36].
There is also evidence that aldosterone may worsen preexisting
alterations in glucose and lipid metabolism [37],[38]. In addition,
a recent study demonstrated that in patients with hypertension,
plasma aldosterone levels were higher in the group with MS in
spite of no differences in plasma renin activity between the groups
with or without MS [10].
Prevalence of the MS is higher in OSAHS patients than in the
general population, but the biological mechanisms underlying the
link between OSAHS and MS are not yet fully understood [3]. In
this study, we evaluated whether aldosterone may play a role in the
development of the MS in OSAHS.
Aldosterone levels were higher in the OSAHS group with MS
and in a multivariate-adjusted analysis aldosterone levels were
significantly associated with the presence of metabolic syndrome,
elevated triglyceride levels and elevated blood pressure. OSAHS
patients with MS presented higher levels of glucose than patients
without MS, but the association between aldosterone and glucose
levels failed to reach statistical significance. Experimental and
clinical evidence support a pathophysiologic link between
OSAHS, beta cell function and glucose metabolism [3],[38].
Moreover, several cross-sectional studies have reported direct
correlations between aldosterone and insulin resistance [27],[30].
Despite these evidences, we found that aldosterone was associated
with the MS, even after adjusting for all of its single components,
such as high glucose levels, which would indicate that the
clustering of these factors per se is associated with aldosterone.
The importance of aldosterone in the incidence of metabolic
syndrome is supported by follow-up sub analyses from the
Figure 3. Aldosterone levels by number of metabolic risk factors.
doi:10.1371/journal.pone.0084362.g003
Table 2. Changes in components of the metabolic syndrome
and in aldosterone, PRA and aldosterone/PRA ratio after 12
month of CPAP treatment (n = 51).
Baseline Follow-up p value
BMI (Kg.m 22) 30.564.5 30.964.5 0.191
Waist circumference (cm) 106.1 107.5 0.706
Glucose (mg/dL) 108622 106633 0.246
Triglycerides (mg/dL) 193662 179675 0.288
HDLc (mg/dL) 51610 54611 0.022
SBP (mmHg) 134616 138620 0.252
DBP (mmHg) 83611 81610 0.311
Creatinine (mg/dL) 0.9560.15 0.9460.15 0.855
PRA (ng/mL/h) 1.461.1 1.360.9 0.765
Aldosterone (ng/dL) 16.768.7 12.669.4 0.012
Aldosterone/PRA ratio 19615 17613 0.274
Hyperaldosteronism (n,%) 9, 19% 2, 4% 0.120
doi:10.1371/journal.pone.0084362.t002
Aldosterone and OSA
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Framingham Offspring Study. In a recent investigation on this
group, among 8 biomarkers representing distinct biological
pathways to the incidence of MS only plasminogen activator
inhibitor-1 (PAI-1) and aldosterone were significantly associated
with the incidence of metabolic syndrome, relations that remained
robust after adjustment for insulin resistance (HOMA-IR). In our
study, aldosterone levels were significantly associated with the
presence of metabolic syndrome. Furthermore, aldosterone levels
tended to increase with an increasing number of MS risk factors,
suggesting that aldosterone excess may predispose or aggravate the
development of metabolic syndrome. At the individual level, future
research should focus on a better understanding the associations of
aldosterone with separate components of MS, including glucose
and lipid metabolism and hypertension.
Recent studies have suggested that aldosterone excess may play
a role in the relation between hypertension and OSAHS
[15],[17],[18]. The mechanisms linking OSAHS and hyperaldo-
steronism are not fully elucidated and it is not clear if whether
aldosterone secretion is cause or consequence of OSAHS [19].
OSAHS may lead to increased aldosterone release via stimulation
of the RAS, which in turn may might contribute to OSAHS
through excess fluid retention and upper airway narrowing
[16],[20]. A recent study demonstrated that treatment with
spironolactone could reduces OSAHS severity in patients with
resistant hypertension [21]. In another study evaluating the effects
of CPAP, a reduction in aldosterone levels after 3 months of CPAP
treatment has been detected [22]. In contrast, Svatikova et al
found that patients with OSAHS without co-existing co morbid-
ities have aldosterone and renin levels similar to healthy subjects
[23]. Despite the fact that our results revealed a significant
association between aldosterone and elevated blood pressure
according to criteria for the MS, there were no differences in
aldosterone levels between normotensive and hypertensive pa-
tients, which may have different reasons. First, we carefully
excluded patients taking antihypertensive medications. The
excluded patients could represent the majority of patients with
elevated blood pressure. This introduces a selection in the study
population and reduces statistical power. Second, the effects of the
medications may be divergent (suppress or increase) on aldoste-
rone levels and renin activity, and methodological differences may
contribute to variability between studies.
Limitations
Some potential confounding factors, such as nutritional status,
physical activity or the interaction between genetic variants, were
not taken into account in our analysis.
Participants were all male. This fact limits the generalizability of
the results to the whole population. We think that future
randomized studies including these measurements are needed to
determine the impact of all these observations on metabolic
dysfunction of OSAHS patients.
Conclusions
This study shows that aldosterone levels are elevated in OSAHS
in comparison to controls, and that CPAP therapy reduces
aldosterone levels. It also shows that aldosterone levels are
associated with the presence of metabolic syndrome, suggesting
that aldosterone excess might predispose or aggravate the
metabolic and cardiovascular complications of OSAHS.
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